We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.
Accreditation Information
Target Audience
The target audience for this activity is oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists charged with the care of patients with multiple myeloma and other hematological malignancies.
Learning Objectives
- Evaluate strategies for the effective treatment of patients with smoldering, newly diagnosed, and relapsed/refractory multiple myeloma
- Compare and contrast approaches for the optimal sequencing of therapies for patients with multiple myeloma throughout different stages of treatment
- Assess various mitigation strategies for treatment-related adverse events that may occur during the care of patients with multiple myeloma
- Discuss tactics for applying clinician experience with using recently approved therapies for multiple myeloma, including bispecific antibodies and others, towards other hematologic malignancies
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty disclosure information coming soon.
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Link for activity evaluation coming soon
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.